Klinikum Altenburger Land GmbH
- Address
- Am Waldessaum 10, 04600 Altenburg, Germany
Analytical, Diagnostic and Therapeutic Techniques and Equipment
The Neurology department at Klinikum Altenburger Land GmbH is exploring state‑of‑the‑art diagnostic tools and therapeutic delivery platforms in early‑stage safety studies. Researchers are applying advanced imaging to track outcomes and evaluating novel device‑assisted treatments for both neurological and musculoskeletal conditions.
- Safety and tolerability assessments of new therapeutic agents
- Implementation of innovative imaging and monitoring techniques
- Integration of device‑based delivery systems in clinical protocols
Seven investigators contribute to a diverse portfolio of eight trials, positioning the site as a hub for translational technology research in Europe.
Cardiovascular Diseases
Within the cardiovascular therapeutic area, the clinic conducts studies aimed at reducing major adverse cardiac events and improving blood pressure control in high‑risk populations. Trials evaluate novel peptide‑based therapies and assess their impact on long‑term heart health.
- Risk reduction strategies for established cardiovascular disease
- Management of hypertension in patients with high cardiovascular risk
- Evaluation of cardiovascular outcomes such as myocardial infarction and heart failure
The research contributes to evidence‑based approaches for patients with both existing heart conditions and those at elevated risk, supporting the site’s commitment to cardiovascular care excellence.
Immune System Diseases
The department is advancing treatment options for autoimmune disorders by investigating FcRn‑targeted immunotherapies in generalized myasthenia gravis. Comparative studies assess efficacy and safety of emerging biologics to modulate the immune response.
- Development of novel monoclonal antibodies for autoimmune neuromuscular disease
- Assessment of patient‑reported functional improvements
- Exploration of immune modulation mechanisms in clinical settings
With a focused team of investigators, the site supports patients seeking alternative therapeutic pathways beyond conventional immunosuppression.
Musculoskeletal Diseases
Research in musculoskeletal health centers on regenerative cell therapies for cartilage repair, employing umbilical‑cord‑derived stem cells combined with collagen scaffolds to treat knee joint defects. The trials measure structural healing and functional recovery.
- Application of mesenchymal stem cells for joint regeneration
- Evaluation of scaffold‑based delivery systems
- Long‑term functional outcome monitoring in knee cartilage repair
This work aligns with the site’s broader aim to restore mobility and quality of life for patients with degenerative joint conditions.
Nervous System Diseases
In the realm of neurological disorders, the clinic investigates acute stroke interventions and cognitive disease therapies. Studies test neuroprotective agents, optimized reperfusion strategies, and novel compounds for Alzheimer’s disease, seeking to improve functional independence and slow disease progression.
- Optimization of reperfusion techniques for acute ischemic stroke
- Evaluation of neuroprotective drugs to enhance post‑stroke recovery
- Assessment of disease‑modifying agents in early‑stage Alzheimer’s disease
By integrating advanced neuroimaging and functional scales, the site aims to deliver tangible benefits to patients facing sudden neurological events and chronic neurodegenerative conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 25 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 14 by active trials.
- 1Janssen Cilag International1active
lock +13 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum Altenburger Land GmbH
lock Showing 1 of 19 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase 2b, multinational, randomized, double-blind study to investigate the efficacy and safety of redasemtide (S-005151) compared with placebo in adult participants with acute ischemic stroke | Shionogi B.V. | Phase II | Not Yet Recruiting | Feb 2024 | Jun 2026 |
IMP list
lock Showing 1 of 25 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Florbetaben (18F) | 2 | Unknown | 2023-09-28 | 2023-09-28 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.